Investor Presentaiton

Novo Nordisk at a glance Investor presentation First three months of 2017 Slide 22 • Global leader in diabetes care A focused pharmaceutical company with leading positions in diabetes, haemophilia and growth hormone • Significant growth opportunities driven by the diabetes pandemic, fuelled by global presence and strong R&D pipeline • High barriers to entry in biologics • Operating profit growth targeting 5% on average • Earnings conversion to cash targeting 90% Cash generated returned to shareholders Global insulin market leadership Global insulin market share: 46% Region Europe: Market share 45% Region China: Market share 54% North America Operations: Market share 37% Region Latin America: Market share 42% Region Japan & Korea: Market share 49% Region AAMEO: Market share 57% changing diabetes ●Global/regional headquarter Source: IMS MAT February 2017 volume figures AAMEO: Africa, Asia, Middle East & Oceania ● Manufacturing • R&D facility novo nordisk

View entire presentation